MAPK1 and intrahepatic cholangiocarcinoma: Collectively, these data proved that circPCNXL2 inhibited the antineoplastic efficacy of trametinib in ICC by activating the phosphorylation of ERK in vivo, which could be a promising strategy in ICC therapy.